2-(7-氟吡咯并[1,2-a]喹喔啉-4-基)2-吡嗪羧酸酰肼盐酸盐 | 917497-70-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-(7-氟吡咯并[1,2-a]喹喔啉-4-基)2-吡嗪羧酸酰肼盐酸盐
• 中文别名: N'-(7-氟吡咯并[1,2-A]喹喔啉-4-基)吡嗪-2-甲酰肼盐酸盐
• 英文名称: SC144
• 英文别名: 2-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl) 2-pyrazinecarboxylic acid hydrazide hydrochloride；SC144 hydrochloride；N'-(7-fluoropyrrolo[1,2-a]quinoxalin-4-yl)pyrazine-2-carbohydrazide;hydrochloride
• CAS: 917497-70-2
• 化学式: C₁₆H₁₁FN₆O*ClH
• 分子量: 358.762
• InChiKey: LKFGGXYXFIICED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.2
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3

反应信息

• 作为产物：
  描述：

  吡嗪-2-甲酰肼 、 4-氯-7-氟吡咯并[1,2-a]喹喔啉 以 乙醇 为溶剂， 反应 5.0h， 以80%的产率得到2-(7-氟吡咯并[1,2-a]喹喔啉-4-基)2-吡嗪羧酸酰肼盐酸盐
  参考文献：
  名称：

  Synthesis and antitumor activities of a series of novel quinoxalinhydrazides

  摘要：

  Recently, we discovered a novel class of anticancer compounds with remarkable potency in a panel of cancer cell lines. A prototype compound, SC144, showed significant in vivo efficacy in mice xenograft models of human breast cancer cells. Herein, we report on a new synthetic route to SC144 and the synthesis of several of its analogues in order to understand required features for activity. A one-step coupling of 7-fluoro-4-chloropyrrolo[1,2-a]quinoxaline with pyrazin-2-carbohydrazide improved the yield significantly. Although several of the analogues showed significant activities, modification of the heteroacyl moiety had a dramatic effect on potency. (c) 2006 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2006.09.073

文献信息

• NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION
  申请人：Neamati Nouri

  公开号：US20090093489A1

  公开（公告）日：2009-04-09

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  新型化合物用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法、含有这些化合物的药物组合物和包装产品、使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法、监测治疗的方法、基因表达谱分析的方法以及调节细胞生长、细胞周期、细胞凋亡或基因表达的方法。
• Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function
  申请人：NEAMATI Nouri

  公开号：US20110034472A1

  公开（公告）日：2011-02-10

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.

  新型化合物用于治疗癌症和与血管生成功能相关的疾病。还公开了制备这些化合物的方法，含有这些化合物的药物组合物和包装产品，使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关的疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法，监测治疗的方法，基因表达谱分析的方法，以及调节细胞生长、细胞周期、凋亡或基因表达的方法。
• NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES
  申请人：Bauer Victor J.

  公开号：US20110034473A1

  公开（公告）日：2011-02-10

  A novel co-crystal of N′-(7-fluoropyrrolo[1,2a]quinoxalin-4-yl)pyrazine-2-carbohydrazide with oxalic acid is disclosed. The disclosed oxalic acid co-crystal demonstrates cancer cell growth inhibition and is more bioavailable than the corresponding free base when administered as a suspension.
• US8058437B2
  申请人：——

  公开号：US8058437B2

  公开（公告）日：2011-11-15